Everolimus in Refractory Testicular Germ Cell Cancer - Trial NCT01466231
Access comprehensive clinical trial information for NCT01466231 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Institute, Slovakia and is currently Completed. The study focuses on Germ Cell Tumor. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National Cancer Institute, Slovakia
Timeline & Enrollment
Phase 2
Nov 01, 2011
Jun 01, 2015
Primary Outcome
Response rate
Summary
Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered
 to the patient until progression, unacceptable toxicity, complete response or inability of
 the subject to comply with study requirements. Feasibility of surgical resection will be
 assessed after every 2 cycles of the treatment in patients with partial response.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01466231
Non-Device Trial